Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Return on Sales (2016 - 2025)

Celldex Therapeutics has reported Return on Sales over the past 16 years, most recently at 672.04% for Q4 2025.

  • Quarterly results put Return on Sales at 672.04% for Q4 2025, down 63196.0% from a year ago — trailing twelve months through Dec 2025 was 167.37% (down 14488.0% YoY), and the annual figure for FY2025 was 167.48%, down 14499.0%.
  • Return on Sales for Q4 2025 was 672.04% at Celldex Therapeutics, down from 86.36% in the prior quarter.
  • Over the last five years, Return on Sales for CLDX hit a ceiling of 3.84% in Q2 2021 and a floor of 672.04% in Q4 2025.
  • Median Return on Sales over the past 5 years was 63.11% (2021), compared with a mean of 101.44%.
  • Peak annual rise in Return on Sales hit 13290bps in 2025, while the deepest fall reached -63196bps in 2025.
  • Celldex Therapeutics' Return on Sales stood at 60.4% in 2021, then soared by 73bps to 16.42% in 2022, then soared by 36bps to 10.48% in 2023, then crashed by -282bps to 40.08% in 2024, then plummeted by -1577bps to 672.04% in 2025.
  • The last three reported values for Return on Sales were 672.04% (Q4 2025), 86.36% (Q3 2025), and 77.53% (Q2 2025) per Business Quant data.